Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD). Although hyperuricemia is a risk factor for CKD progression, the causal role of uric acid remains controversial in patients with CKD and asymp...
Main Authors: | Hee Jung Jeon, Jieun Oh, Dong Ho Shin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0218510 |
Similar Items
-
Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy
by: M. S. Eliseev
Published: (2018-04-01) -
To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease
by: Dong Ho Shin
Published: (2019-09-01) -
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
by: Theodoros Eleftheriadis, et al.
Published: (2017-09-01) -
Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
by: Davide Viggiano, et al.
Published: (2018-04-01) -
Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
by: Gaurav Sharma, et al.
Published: (2021-05-01)